Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:20371689rdf:typepubmed:Citationlld:pubmed
pubmed-article:20371689lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:20371689lifeskim:mentionsumls-concept:C0086418lld:lifeskim
pubmed-article:20371689lifeskim:mentionsumls-concept:C0332174lld:lifeskim
pubmed-article:20371689lifeskim:mentionsumls-concept:C0003250lld:lifeskim
pubmed-article:20371689lifeskim:mentionsumls-concept:C0280100lld:lifeskim
pubmed-article:20371689lifeskim:mentionsumls-concept:C0140080lld:lifeskim
pubmed-article:20371689lifeskim:mentionsumls-concept:C2346815lld:lifeskim
pubmed-article:20371689lifeskim:mentionsumls-concept:C0231491lld:lifeskim
pubmed-article:20371689lifeskim:mentionsumls-concept:C0920321lld:lifeskim
pubmed-article:20371689lifeskim:mentionsumls-concept:C0205179lld:lifeskim
pubmed-article:20371689pubmed:issue8lld:pubmed
pubmed-article:20371689pubmed:dateCreated2010-4-16lld:pubmed
pubmed-article:20371689pubmed:abstractTextA phase I study was conducted to evaluate the pharmacokinetics, pharmacodynamics, safety, and tolerability of R1507-a fully human IgG1 type monoclonal antibody directed against the human insulin-like growth factor-I receptor. Experimental design: Patients with advanced solid tumors were assigned to receive i.v. R1507 weekly (qW), starting with 1 mg/kg. Subsequent cohorts were dosed at 3 and then 9 mg/kg. An additional 12 patients received 9 mg/kg R1507 qW. Patients remained on the study until the development of a dose-limiting toxicity or progressive disease.lld:pubmed
pubmed-article:20371689pubmed:languageenglld:pubmed
pubmed-article:20371689pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20371689pubmed:citationSubsetIMlld:pubmed
pubmed-article:20371689pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20371689pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20371689pubmed:statusMEDLINElld:pubmed
pubmed-article:20371689pubmed:monthAprlld:pubmed
pubmed-article:20371689pubmed:issn1078-0432lld:pubmed
pubmed-article:20371689pubmed:authorpubmed-author:PatnaikAmitaAlld:pubmed
pubmed-article:20371689pubmed:authorpubmed-author:EckhardtS...lld:pubmed
pubmed-article:20371689pubmed:authorpubmed-author:AisnerJosephJlld:pubmed
pubmed-article:20371689pubmed:authorpubmed-author:KurzrockRazel...lld:pubmed
pubmed-article:20371689pubmed:authorpubmed-author:WarrenTerriTlld:pubmed
pubmed-article:20371689pubmed:authorpubmed-author:GoreLiaLlld:pubmed
pubmed-article:20371689pubmed:authorpubmed-author:GreigGerardGlld:pubmed
pubmed-article:20371689pubmed:authorpubmed-author:EidJoseph EJElld:pubmed
pubmed-article:20371689pubmed:authorpubmed-author:BenjaminRober...lld:pubmed
pubmed-article:20371689pubmed:authorpubmed-author:HabbenKaiKlld:pubmed
pubmed-article:20371689pubmed:authorpubmed-author:LeongStephenSlld:pubmed
pubmed-article:20371689pubmed:authorpubmed-author:McCarthyCinar...lld:pubmed
pubmed-article:20371689pubmed:issnTypePrintlld:pubmed
pubmed-article:20371689pubmed:day15lld:pubmed
pubmed-article:20371689pubmed:volume16lld:pubmed
pubmed-article:20371689pubmed:ownerNLMlld:pubmed
pubmed-article:20371689pubmed:authorsCompleteYlld:pubmed
pubmed-article:20371689pubmed:pagination2458-65lld:pubmed
pubmed-article:20371689pubmed:dateRevised2011-8-2lld:pubmed
pubmed-article:20371689pubmed:meshHeadingpubmed-meshheading:20371689...lld:pubmed
pubmed-article:20371689pubmed:meshHeadingpubmed-meshheading:20371689...lld:pubmed
pubmed-article:20371689pubmed:meshHeadingpubmed-meshheading:20371689...lld:pubmed
pubmed-article:20371689pubmed:meshHeadingpubmed-meshheading:20371689...lld:pubmed
pubmed-article:20371689pubmed:meshHeadingpubmed-meshheading:20371689...lld:pubmed
pubmed-article:20371689pubmed:meshHeadingpubmed-meshheading:20371689...lld:pubmed
pubmed-article:20371689pubmed:meshHeadingpubmed-meshheading:20371689...lld:pubmed
pubmed-article:20371689pubmed:meshHeadingpubmed-meshheading:20371689...lld:pubmed
pubmed-article:20371689pubmed:meshHeadingpubmed-meshheading:20371689...lld:pubmed
pubmed-article:20371689pubmed:meshHeadingpubmed-meshheading:20371689...lld:pubmed
pubmed-article:20371689pubmed:meshHeadingpubmed-meshheading:20371689...lld:pubmed
pubmed-article:20371689pubmed:meshHeadingpubmed-meshheading:20371689...lld:pubmed
pubmed-article:20371689pubmed:meshHeadingpubmed-meshheading:20371689...lld:pubmed
pubmed-article:20371689pubmed:meshHeadingpubmed-meshheading:20371689...lld:pubmed
pubmed-article:20371689pubmed:meshHeadingpubmed-meshheading:20371689...lld:pubmed
pubmed-article:20371689pubmed:meshHeadingpubmed-meshheading:20371689...lld:pubmed
pubmed-article:20371689pubmed:year2010lld:pubmed
pubmed-article:20371689pubmed:articleTitleA phase I study of weekly R1507, a human monoclonal antibody insulin-like growth factor-I receptor antagonist, in patients with advanced solid tumors.lld:pubmed
pubmed-article:20371689pubmed:affiliationDepartment of Investigational Cancer Therapeutics, M.D. Anderson Cancer Center, Houston, TX 77030, USA. rkurzroc@mdanderson.orglld:pubmed
pubmed-article:20371689pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:20371689pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
pubmed-article:20371689pubmed:publicationTypeClinical Trial, Phase Illd:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:20371689lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:20371689lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:20371689lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:20371689lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:20371689lld:pubmed